Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma Clinical Trial
Official title:
Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma
| Verified date | January 2019 |
| Source | Leti Pharma GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
| Status | Completed |
| Enrollment | 634 |
| Est. completion date | July 30, 2018 |
| Est. primary completion date | July 30, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 12 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Availability of an appropriately signed and dated informed consent before any study specific examination, - Clinical history of at least 2 years of seasonal allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma due to birch pollen allergy that has required repeated use of symptomatic treatment, - Patients must have a minimum level of perception of symptoms from previous seasons defined as at least a moderate symptom level (i.e. a score of 2 on the 4-point-Likert scale) in at least 2 symptom categories prior to randomization, - Lung function = 80% of the predicted normal value, - IgE-mediated sensitization has to be verified by: - suggestive medical history, and - specific IgE reactivity to birch pollen (CAP-RAST = 2), and - a positive SPT to birch pollen at screening or within 1 months prior to the screening visit. An SPT is considered positive if it results in a wheal diameter of at least 3.0 mm - Internet access so that patients can complete the eDiary daily via internet during all 5 pollen seasons covered by the study protocol. Exclusion Criteria: - History of significant clinical manifestations of allergy as a result of sensitization against co-allergies, particularly—but not limited to—grass or weed pollen and perennial allergens (e.g. house dust mites, cat or dog). - History of anaphylactic reaction. - Moderate or severe persistent asthma (GINA 3 or 4). - Mild persistent asthma (GINA 2), according to the Global Initiative for Asthma Guidelines, necessitating treatment with inhaled glucocorticoids at a daily dose level of > 400 µg budesonide dose equivalents. - Lung function < 80% of the predicted normal value (for PEF: highest result of 3 measurements). - Acute or chronic inflammatory or infectious airway diseases including recurrent acute or chronic sinusitis. - Chronic structural diseases of the affected organs (e.g. eye, nose, lung). - History or presence of confirmed or potential diseases of the immune system including autoimmune diseases and immune deficiencies of actual clinical relevance. - Any disease that prohibits the use of adrenaline (e.g. hyperthyroidism). - Atopic dermatitis with SCORAD >30 in the past or at screening. - Ongoing or past full courses of SIT against birch pollen within the last 5 years. - Topical and systemic treatment with ß-blockers. - Concomitant treatment with substances interfering with the immune system beginning 1 week prior to start of treatment. - Use of systemic corticosteroids within 3 months prior to Visit 1-1. - Immunization with vaccines within 7 days prior to Visit 1-1. - Treatment with antihistamines for any reason other than allergic symptoms due to birch pollen allergy. - Changed residence between geographical regions since the last birch pollen season or not staying in the geographical region during the pre-determined birch pollen season. - Nursing (lactating) women or women with a positive pregnancy test at the screening visit. Women of childbearing potential must be using highly effective contraception during participation in this clinical study. A highly effective method of birth control is defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, or vasectomised partner. |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Hautarztpraxis | Berlin | |
| Germany | Klinik und Poliklinik für Dermatologie und Allergologie der Universität | Bonn |
| Lead Sponsor | Collaborator |
|---|---|
| Leti Pharma GmbH |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Proof of efficacy (superiority vs. placebo) by means of the combined Symptom and Medication Score (SMS). | For the primary outcome the SMS of nasal and ocular symptoms and their respective Rescue Medication score is used to assess efficacy of the perennial treatment regimen of Depigoid Birch 5000 DPP/mL versus placebo after 5 years (comprising 3 years of treatment plus 2 years treatment-free follow-up). An interim analysis will be conducted after 2 years. Data are captured via eDiary to be completed by the patients during each of the 5 pollen seasons within the duration of the study, starting prior to onset of pollen flight until after the end of the pollen seasons. |
after 5 years | |
| Secondary | Symptom score (SS) during the 1st, 3rd, and 4th pollen seasons. | Differences between treatment groups also including pulmonary symptoms and for asthmatic/non-asthmatic patients. Data are captured via eDiary to be completed by the patients during each of the 5 pollen seasons within the duration of the study, starting prior to onset of pollen flight until after the end of the pollen seasons. |
after 1 year, 2 years, 3 years, 4 years and 5 years | |
| Secondary | Rescue Medication Score (RMS) during the 1st, 3rd, and 4th pollen season (futility and interim analyses). | Differences between treatment groups also including pulmonary symptoms and for asthmatic/non-asthmatic patients. Data are captured via eDiary to be completed by the patients during each of the 5 pollen seasons within the duration of the study, starting prior to onset of pollen flight until afte the end of the pollen seasons. |
after 1 year, 2 years, 3 years, 4 years and 5 years | |
| Secondary | combined Symptoms and Rescue Medication Score (SMS) during the 1st, 3rd, and 4th pollen season including pulmonary symptoms. | Differences between treatment groups, during all 5 pollen seasons also including pulmonary symptoms and for asthmatic/non-asthmatic patients. Data are captured via eDiary to be completed by the patients during each of the 5 pollen seasons within the duration of the study, starting prior to onset of pollen flight until after the end of the pollen seasons. |
after 1 year, 2 years, 3 years and 4 years | |
| Secondary | Rhinitis Quality of Life Questionnaire (RQLQ) resp. RQLQ for adolescent patients (AdolRQLQ) | Changes to baseline and difference between treatment groups during all 5 pollen seasons | Screening and after 1 year, 2 years, 3 years, 4 years and 5 years | |
| Secondary | Immunology parameters (Total IgE, specific IgE, specific IgG1 and IgG4) | Differences within patients and between treatment groups | Screening, after years 1, 2, 3 and 5 (resp. end of study) | |
| Secondary | Disease modifying effect after 5 years | Difference between treatment groups. Incidence of asthma and new sensitizations. | after 5 years | |
| Secondary | Clinical chemistry: Number of patients with outside range values | Differences between treatment groups | Screening, after years 2, 3 and 5 | |
| Secondary | Adverse events: number of patients with AEs/SAEs | Including symptoms reported by patients in eDiary. Differences between treatment groups including but not limited to differences in severity levels of systemic reactions (SRs), immediate and local reaction including calculation of ratios per injection | throughout the whole study duration | |
| Secondary | Serum levels of Aluminium hydroxide (Pharmacokinetics) | Serum Aluminium hydroxide levels are assessed in a subgroup of 24 patients. Differences between treatment groups (adult patients only) Sampling: prior to 1st application of IMP, 4 time points after 1st, 2nd and 10th application (after 1 year). 24 hrs. urine at these 3 time points | prior and after 1st and 2nd application of IMP and after 1 year | |
| Secondary | Vitamin D3 level | Possible influence on specific immunotherapy. Exploratory evaluation | baseline and end of study | |
| Secondary | Hematology: Number of patients with outside range values | Differences between treatment groups | Screening, after years 2, 3 and 5 |